FEB-01-05

	<del></del>	1			
TRANSMITTAL FORM		Application Number		08/704,159	FECEIVED
		Filing Date		August 28, 1996	CENTRAL FAX CENTER
		First Name	d Inventor	Williams	
(to be used for all correspondence after initial filing)		Group Art Unit		1648	FEB 0 8 2005
		Examiner Name		Li, B.Q.	
Total Number of Pages in This Submission 3		Attorney Docket Number		D-2939CIP	
ENCLOSURES (check all that apply)					
Fee Transmittal Form	Assignment Papers (for an Apptication)		After Allowance Communication to Group		1
Fee Attached	Drawing(s)	Drawing(s)		al Communication to Board of terferences	f Appeals
Amendment/Reply	Licensing-relate	ed Papers	Appea (Appea		
After Final Petition			Propri	:	
Affidavits/declaration(s) Petition to Conve			Status	İ	
Extension of Time Request	nsion of Time Request Power of Attorno Revocation Change of Corre		Other Enclosure(s) . (please identity below)		.
Express Abandonment Terminal Di		New Pow		n of Power of Attomey er of Attorney and State	and ement
Information Disclosure Statement	Request for Re	fund	Under 37 CFR 3.73(b)		
Certifled Copy of Priority Document(s)	CD, Number of CD(s)				
Response to Missing Parts/ Incomplete Application Remarks			<u> </u>		
Response to Missing Parts under 37 CFR 1.52 or 1.53					
S	IGNATURE OF APPLICA	ANT, ATTOR	NEY, OR AGE	VT	
Firm Frank J. Uxa or Individual Name Registration No. 25,612					
9-1/1/					
Signature Many 4th					
Date 2/8/05					
CERTIFICATE OF TRANSMISSION/MAILING					
I hereby certify that this correspondence is being facsimile transmitted to the USPTO at fax number 703-872-9305, or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.					deposited signer for
Typed or printed name Janet N					
Signature Date 2/8/2005					
The Information contained in this facsimile message is privileged and confidential information intended for the use of the individual or entity named above. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you have received this fax in error, please immediately notify us by telephone and return the original message to us at the above address via the U.S. Postal Service.					

Docket 17350 CIP5 / Appl. No. 08/704,159 Power of Attorney

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appl. No.

: 08/704,159

Confirmation No.

8816

Applicant

: Williams et al.: August 28, 1996

Filed Title

: SOLUBLE RECOMBINANT BOTULINUM TOXIN PROTEINS

RECEIVED

TC/A.U.

: 1600/1648

Examiner

: LI, B.Q.

FEB 0 8 2005

Docket No.

: D2939-CIP / 17350 CIP5

Customer No.

: 33197

## REVOCATION OF POWER OF ATTORNEY AND NEW POWER OF ATTORNEY AND STATEMENT UNDER 37 CFR 3.73(b)

Allergan, Inc., and Allergan Botox Limited, as assignees of record of the entire title, right, and interest of the above-identified application hereby revoke all previous powers of attorney given in the above-identified application, and hereby appoint the following practitioners as their attorney(s) or agent(s) with full power of substitution to prosecute the above-identified application, and to transact all business in the United States Patent and Trademark Office connected therewith:

Frank J. Uxa, Reg. No. 25,612, Martin A. Voet, Reg. No. 25,208, Robert J. Baran, Reg. No. 25,806, Stephen Donovan, Reg. No. 33,433, Carlos A. Fisher, Reg. No. 36,510, Brent A. Johnson, Reg. No. 51,851, Dean G. Stathakis, Reg. No. 54,465, Linda Allyson Fox, Reg. No. 38,883, Greg S. Hollrigel, Reg. No. 45,374.

The correspondence address for the above-identified application should be the address associated with **Customer Number 33197**. All correspondence should be directed to Frank J. Uxa.

Docket 17350 CIP5 / Appl. No. 08/704,159 Power of Attorney

## Statement Under 37 CFR 3.73(b)

Allergan, Inc., and Allergan Botox Limited, (hereinafter Allergan) states that Allergan is the assignee of record of the entire right, title, and interest in the above-identified patent application by virtue of a chain of title from the inventors of the above-identified application to Allergan as shown in the assignments below:

- From James A. Williams and Bruce S. Thalley to Ophidian
   Pharmaceuticals, Inc., as recorded on December 2, 1996 at reel 8341,
   frame 0273; and
- 2. From Ophidian Pharmaceuticals, Inc. to Allergan, Inc., and Allergan Botox Limited, as recorded on September 26, 2000 at reel 011183, frame 0764.

Signed this <u>25</u> day of January 2005.

Allergan, Inc.

Martin A Voot

Its: Assistant Secretary

Signed this 26 day of January 2005.

Allergan Botox Limited

Douglas S. Ingram

Its: Company Secretary

Page 2 of 2